Glycoengineering of AAV-delivered monoclonal antibodies yields increased ADCC activity.

Termini, James M; Martinez-Navio, José M; Gao, Guangping; Fuchs, Sebastian P; Desrosiers, Ronald C

Termini, James M; Martinez-Navio, José M; Gao, Guangping; Fuchs, Sebastian P; Desrosiers, Ronald C.

Afiliación

Termini JM; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.
Martinez-Navio JM; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.
Gao G; Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA.
Fuchs SP; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.
Desrosiers RC; Department of Pathology, University of Miami Miller School of Medicine, Miami, FL, USA.

Mol Ther Methods Clin Dev ; 20: 204-217, 2021 Mar 12.

Article en En | MEDLINE | ID: mdl-33426147

Palabras clave

adeno-associated virus; antibody-dependent cellular cytotoxicity; broadly neutralizing antibodies; fucosyltransferase 8; gene therapy; glycoengineering; immunotherapy; viral reservoir

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2021 Tipo del documento: Article